(Q38074898)

28 August 2017

1 reference

title

Nonalcoholic fatty liver disease: current issues and novel treatment approaches (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

28 August 2017

1 reference

1 reference

1 reference

Romina Lomonaco

1

1 reference

28 August 2017

Nishanth E Sunny

series ordinal

2

1 reference

28 August 2017

Fernando Bril

series ordinal

3

1 reference

28 August 2017

Kenneth Cusi

series ordinal

4

1 reference

28 August 2017

1 January 2013

1 reference

28 August 2017

1 reference

28 August 2017

73

1 reference

28 August 2017

1

1 reference

28 August 2017

1-14

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-012-0004-0

28 August 2017

0 references

cites work

The natural history of non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Genetic and environmental susceptibility to non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Some inflammatory cytokine levels, iron metabolism and oxidan stress markers in subjects with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Novel insights into the pathophysiology of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Mitochondria in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Non-alcoholic fatty liver disease: is bariatric surgery the answer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Liver fat in the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Evolution of nonalcoholic fatty liver disease recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Interrelationship between fatty liver and insulin resistance in the development of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Postprandial hyperinsulinemia is universal in non-diabetic patients with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Postprandial insulin secretion pattern is associated with histological severity in non-alcoholic fatty liver disease patients without prior known diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Influence of ethnicity on histological differences in non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Waist circumference correlates with liver fibrosis in children with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Newly diagnosed diabetes mellitus as a risk factor for serious liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Long-term follow-up of patients with NAFLD and elevated liver enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Silent non-alcoholic fatty liver disease-a clinical-histological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Long-term follow-up of patients with nonalcoholic fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Decreased survival of subjects with elevated liver function tests during a 28-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

The role of adipose tissue and lipotoxicity in the pathogenesis of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Alanine aminotransferase, gamma-glutamyltransferase (GGT) and all-cause mortality: results from a population-based Danish twins study alanine aminotransferase, GGT and mortality in elderly twins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Liver disease in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Intramitochondrial crystalline inclusions in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Abnormal hepatic energy homeostasis in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Disordered lipid metabolism and the pathogenesis of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Mechanisms of disease:Molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Ceramides in insulin resistance and lipotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Mechanisms for insulin resistance: common threads and missing links

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

The inflammasome puts obesity in the danger zone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Nonalcoholic fatty liver disease in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Transient elastography for the noninvasive assessment of liver fibrosis: a multicentre Canadian study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Exercise training reduces fatty acid availability and improves the insulin sensitivity of glucose metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Metformin in non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Metformin in the treatment of patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Potential for statins in the chemoprevention and management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

A pilot trial of pentoxifylline in nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Plasma metabolomic profile in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0004-0

Statins and hepatic steatosis: perspectives from the Dallas Heart Study

21 January 2018

1 reference

12 December 2020

Histological findings in the liver before and after gastric bypass

1 reference

12 December 2020

Nonalcoholic fatty liver disease

1 reference

12 December 2020

Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study

1 reference

12 December 2020

Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment.

1 reference

12 December 2020

The natural history of nonalcoholic fatty liver disease: a clinical histopathological study

1 reference

12 December 2020

Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis

1 reference

12 December 2020

Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series

1 reference

12 December 2020

Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis

1 reference

12 December 2020

Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial

1 reference

12 December 2020

A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM.

1 reference

12 December 2020

Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis

1 reference

12 December 2020

Lipid targets during statin treatment in dyslipidemic patients affected by nonalcoholic fatty liver disease

1 reference

12 December 2020

Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis

1 reference

12 December 2020

Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial

1 reference

12 December 2020

Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study

1 reference

12 December 2020

Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis

1 reference

12 December 2020

A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients

1 reference

12 December 2020

Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality

1 reference

12 December 2020

Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years

1 reference

12 December 2020

Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study

1 reference

12 December 2020

A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease

1 reference

12 December 2020

Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies

1 reference

12 December 2020

Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia.

1 reference

12 December 2020

Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis

1 reference

12 December 2020

Bariatric surgery for non-alcoholic steatohepatitis in obese patients

1 reference

12 December 2020

Final results of a long-term, clinical follow-up in fatty liver patients

1 reference

12 December 2020

Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study

1 reference

12 December 2020

Molecular mediators of hepatic steatosis and liver injury

1 reference

12 December 2020

Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease

1 reference

12 December 2020

Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents

1 reference

12 December 2020

Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies

1 reference

12 December 2020

10.1007/S40265-012-0004-0

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

0 references

1 reference